• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肯尼亚一家三级转诊医院胰腺癌患者的临床病理特征及治疗结果

Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya.

作者信息

Muchiri Sheila W, Ogutu Elly O, Oyiro Peter O, Aabakken Lars

机构信息

Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi 00100, Kenya.

World Gastroenterology Organisation Nairobi Training Center, Nairobi 00100, Kenya.

出版信息

Ecancermedicalscience. 2024 Mar 19;18:1682. doi: 10.3332/ecancer.2024.1682. eCollection 2024.

DOI:10.3332/ecancer.2024.1682
PMID:38566769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10984841/
Abstract

The global incidence of pancreatic cancer (PC) continues to steadily increase whereas its prognosis remains poor. Previous studies have suggested worse outcomes among individuals of African descent. The characteristics of patients with PC in Kenya, and their contemporary management and survival outcomes remain largely unknown. This study aimed to describe the clinical and pathologic characteristics, management, and outcomes of patients diagnosed with PC at Kenyatta National Hospital (KNH), a tertiary referral hospital in Kenya. Records of 242 patients diagnosed with PC at KNH between 1st January 2014 and 30th September 2021 were assessed in this retrospective cohort study. Data on their clinical, histopathologic, and treatment characteristics was presented as mean (± standard deviation) and/or median (interquartile range) for continuous variables and frequency (percentage) for categorical variables. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis. PC occurred in a young population, the median age being 58.5 years (inter-quartile range 35-88). The majority of tumours (54%) were metastatic at diagnosis, while 28% and 14% were stage III and stage I/II, respectively. Surgical resections with curative intent were performed on 7% overall and 44% of stage I/II cases. The majority of patients with stage I/II disease (52.9%) received chemotherapy whereas the majority with stage III and IV disease received the best supportive care only (62.7% and 64.9%, respectively). Patients who underwent surgical resection (HR for mortality 0.20, 95% CI 0.05-0.83, p = 0.021) and chemotherapy (HR for mortality 0.15, 95% CI 0.08-0.29, p < 0.001) had significantly improved survival, reflecting a more favourable stage of the disease more amenable to aggressive therapies. The median survival time was 3 months and the 1-year survival rate was 32%.

摘要

胰腺癌(PC)的全球发病率持续稳步上升,但其预后仍然很差。先前的研究表明,非洲裔个体的预后更差。肯尼亚胰腺癌患者的特征、他们当前的治疗情况和生存结果在很大程度上仍然未知。本研究旨在描述在肯尼亚一家三级转诊医院——肯雅塔国家医院(KNH)被诊断为胰腺癌的患者的临床和病理特征、治疗情况及结果。在这项回顾性队列研究中,评估了2014年1月1日至2021年9月30日期间在KNH被诊断为胰腺癌的242例患者的记录。连续变量的临床、组织病理学和治疗特征数据以均值(±标准差)和/或中位数(四分位间距)表示,分类变量以频率(百分比)表示。采用Kaplan-Meier法和Cox比例风险比进行生存分析。胰腺癌发生在年轻人群中,中位年龄为58.5岁(四分位间距35 - 88岁)。大多数肿瘤(54%)在诊断时已发生转移,而分别有28%和14%为III期和I/II期。总体上7%的患者以及44%的I/II期病例接受了根治性手术切除。大多数I/II期疾病患者(52.9%)接受了化疗,而大多数III期和IV期疾病患者仅接受了最佳支持治疗(分别为62.7%和64.9%)。接受手术切除的患者(死亡风险比为0.20,95%置信区间0.05 - 0.83,p = 0.021)和接受化疗的患者(死亡风险比为0.15,95%置信区间0.08 - 0.29,p < 0.001)的生存情况有显著改善,这反映出疾病处于更有利的阶段,更适合积极治疗。中位生存时间为3个月,1年生存率为32%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/eac6f58ea8b6/can-18-1682fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/4d7e8e988f75/can-18-1682fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/6b0b71a00db2/can-18-1682fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/eac6f58ea8b6/can-18-1682fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/4d7e8e988f75/can-18-1682fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/6b0b71a00db2/can-18-1682fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccce/10984841/eac6f58ea8b6/can-18-1682fig3.jpg

相似文献

1
Clinicopathologic characteristics and treatment outcomes of pancreatic cancer patients at a tertiary referral hospital in Kenya.肯尼亚一家三级转诊医院胰腺癌患者的临床病理特征及治疗结果
Ecancermedicalscience. 2024 Mar 19;18:1682. doi: 10.3332/ecancer.2024.1682. eCollection 2024.
2
Delays in diagnosis, referral and management of head and neck cancer presenting at Kenyatta National Hospital, Nairobi.在内罗毕肯雅塔国家医院就诊的头颈癌患者在诊断、转诊及治疗方面的延误情况。
East Afr Med J. 2006 Apr;83(4):85-91. doi: 10.4314/eamj.v83i4.9421.
3
Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the Kenyatta National Hospital, Nairobi.内罗毕肯雅塔国家医院神经母细胞瘤患儿的临床病理特征及治疗结果
East Afr Med J. 2009 Dec;86(12 Suppl):S39-46. doi: 10.4314/eamj.v86i12.62899.
4
Survival of cervical cancer patients at Moi teaching and Referral Hospital, Eldoret in western Kenya.肯尼亚西部埃尔多雷特莫伊教学与转诊医院的宫颈癌患者生存情况。
BMC Cancer. 2023 Nov 13;23(1):1104. doi: 10.1186/s12885-023-11506-w.
5
Predictors of survival outcomes among patients with gastric cancer in a leading tertiary, teaching and referral hospital in Kenya.肯尼亚一家领先的三级教学和转诊医院胃癌患者生存结果的预测因素。
Cancer Med. 2023 Feb;12(4):4147-4160. doi: 10.1002/cam4.5275. Epub 2022 Sep 29.
6
Survival Outcomes Among Pancreatic Cancer Patients at Kenyatta National Hospital.肯尼亚国家医院胰腺癌患者的生存结果。
J Gastrointest Cancer. 2022 Dec;53(4):958-964. doi: 10.1007/s12029-021-00723-w. Epub 2021 Oct 3.
7
An assessment of survival outcomes among ovarian cancer patients at the National and Referral Hospital in Kenya.肯尼亚国家和转诊医院卵巢癌患者生存结果评估。
Cancer Rep (Hoboken). 2024 Feb;7(2):e1986. doi: 10.1002/cnr2.1986.
8
Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma.术前化疗敏感性与胃腺癌患者术后生存的关系。
JAMA Netw Open. 2021 Nov 1;4(11):e2135340. doi: 10.1001/jamanetworkopen.2021.35340.
9
Stroke Mortality in Kenya's Public Tertiary Hospitals: A Prospective Facility-Based Study.肯尼亚公立三级医院的卒中死亡率:一项基于机构的前瞻性研究。
Cerebrovasc Dis Extra. 2018;8(2):70-79. doi: 10.1159/000488205. Epub 2018 Jun 12.
10
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.治疗不公平和种族与胰腺导管腺癌生存的关联。
JAMA Surg. 2020 Feb 1;155(2):e195047. doi: 10.1001/jamasurg.2019.5047. Epub 2020 Feb 19.

引用本文的文献

1
Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study.巴基斯坦胰腺导管腺癌人群的蛋白质组学生物标志物分析:一项回顾性队列研究。
Biomark Med. 2024;18(21-22):969-982. doi: 10.1080/17520363.2024.2416888. Epub 2024 Nov 7.

本文引用的文献

1
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.FOLFIRINOX 对比吉西他滨作为胰腺癌辅助治疗的 5 年结果:一项随机临床试验。
JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829.
2
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
3
COVID-19 and access to cancer care in Kenya: patient perspective.肯尼亚的 COVID-19 与癌症护理的可及性:患者视角。
Int J Cancer. 2022 May 1;150(9):1497-1503. doi: 10.1002/ijc.33910. Epub 2022 Jan 7.
4
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.国际糖尿病联盟(IDF)糖尿病地图集:2021 年全球、区域和国家糖尿病患病率估算值以及 2045 年预测值。
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
5
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.胰腺导管腺癌临床实践指南(第 2.2021 版),NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
A War on Two Fronts: Cancer Care in the Time of COVID-19.两面作战:新冠疫情时期的癌症照护
Ann Intern Med. 2020 Jun 2;172(11):756-758. doi: 10.7326/M20-1133. Epub 2020 Mar 27.
8
Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.术前手术切除后完成辅助化疗在胰腺癌中并不常见,但与改善生存有关。
Ann Surg Oncol. 2019 Nov;26(12):4108-4116. doi: 10.1245/s10434-019-07602-6. Epub 2019 Jul 16.
9
Racial Disparities and Trends in Pancreatic Cancer Incidence and Mortality in the United States.美国胰腺癌发病率和死亡率的种族差异和趋势。
Clin Gastroenterol Hepatol. 2020 Jan;18(1):171-178.e10. doi: 10.1016/j.cgh.2019.05.059. Epub 2019 Jun 13.
10
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.胰腺癌的流行病学:全球趋势、病因及风险因素
World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166. Epub 2019 Feb 26.